No photo of Jacob Haaber Christensen

Jacob Haaber Christensen

1991 …2020

Research output per year

If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Jacob Haaber Christensen is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 10 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output

Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 real-world patients

Jakobsen, L. H., Ellin, F., Smeland, K. B., Wästerlid, T., Christensen, J. H., Jørgensen, J. M., Josefsson, P. L., Øvlisen, A. K., Holte, H., Blaker, Y. N., Grauslund, J. H., Bjørn, J., Molin, D., Lagerlöf, I., Smedby, K. E., Colvin, K., Thanarajasingam, G., Maurer, M. J., Habermann, T. M., Song, K. W. & 4 others, Zhu, K. Y., Gerrie, A. S., Cheah, C. Y. & El-Galaly, T. C., 4. Feb 2020, In : British Journal of Haematology.

Research output: Contribution to journalJournal articleResearchpeer-review

  • Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma

    Lenz, G., Hawkes, E., Verhoef, G., Haioun, C., Thye Lim, S., Seog Heo, D., Ardeshna, K., Chong, G., Haaber, J., Shi, W., Gorbatchevsky, I., Lippert, S., Hiemeyer, F., Piraino, P., Beckmann, G., Peña, C., Buvaylo, V., Childs, B. H. & Salles, G., 14. Feb 2020, In : Leukemia.

    Research output: Contribution to journalJournal articleResearchpeer-review

    Open Access
  • Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

    ECHELON-2 Study Group, 19. Jan 2019, In : Lancet. 393, 10168, p. 229-240

    Research output: Contribution to journalJournal articleResearchpeer-review

    Open Access
  • Chimeric Antigen Receptor T Cells Targeting CD79b Show Efficacy in Lymphoma with or without Cotargeting CD19

    Ormhøj, M., Scarfò, I., Cabral, M. L., Bailey, S. R., Lorrey, S. J., Bouffard, A. A., Castano, A. P., Larson, R. C., Riley, L. S., Schmidts, A., Choi, B. D., Andersen, R. S., Cédile, O., Nyvold, C. G., Haaber, J., Gjerstorff, M. F., Ditzel, H. J., Weinstock, D. M., Barington, T., Frigault, M. J. & 1 others, Maus, M. V., 1. Dec 2019, In : Clinical Cancer Research. 25, 23, p. 7046-7057

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Clinical prognostic scores are poor predictors of overall survival in various types of malignant lymphomas

    Biccler, J. L., El-Galaly, T. C., Bøgsted, M., Jørgensen, J., de Nully Brown, P., Poulsen, C. B., Starklint, J., Juul, M. B., Christensen, J. H., Josefsson, P., Dessau, A. & Jakobsen, L. H., Jun 2019, In : Leukemia and Lymphoma. 60, 6, p. 1580-1583

    Research output: Contribution to journalJournal articleResearchpeer-review

    Activities

    • 2 Membership of research networks or expert groups
    • 1 Organisation or participation in workshops, courses or seminars

    The Danish Multidisciplinary Cancer Groups (DMCG), Denmark (External organisation)

    Jacob Haaber Christensen (Member)
    2019 → …

    Activity: MembershipMembership of research networks or expert groups

    The Danish Multidisciplinary Cancer Groups (DMCG), Denmark (External organisation)

    Jacob Haaber Christensen (Member)
    2019 → …

    Activity: MembershipMembership of research networks or expert groups

    13th International Myeloma Workshop

    Jacob Haaber Christensen (Participant)
    3. May 20116. May 2011

    Activity: Attending an eventOrganisation or participation in workshops, courses or seminars